News Search Results
Oct 30, 2025, 09:00 ET Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders
About Kiora Pharmaceuticals Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules
More news about: RARE-X
Oct 30, 2025, 08:48 ET MLTX INVESTOR ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
The litigation is focused on the propriety of MoonLake's statements about the trial design and data for SLK. The clinical stage biotechnology company is focused on skin inflammatory diseases driven by a cytokines known as IL-17A and IL-17F. Central to SLK's commercial
More news about: Hagens Berman Sobol Shapiro LLP
Oct 30, 2025, 08:33 ET STEMup Science and Technology Institute™ and Connexis Search Group Launch National Partnership to Advance Fractional Leadership and Workforce Innovation in STEM and Life Sciences
seeking flexible career and advisory roles within high-growth ventures. The initiative will pilot fractional executive placements within biotechnology and technology companies while expanding STEMup's Pittsburgh Innovators Apprenticeship Program™ (PIAP™)—a workforce pipeline integrating
More news about: STEMup Science & Technology Institute
Oct 30, 2025, 08:30 ET NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression
NeuroKaire, a pioneer in precision psychiatry and neurology, has launched an R&D collaboration with Compass Pathways, a leading biotechnology company dedicated to transforming mental health care.
More news about: NeuroKaire
Oct 30, 2025, 08:30 ET Using Acceleration Levers to Expedite Late Phase CMC Programs for Therapeutic Proteins, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 30, 2025, 08:30 ET Real-World Clinical Data and Cohort Design, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 30, 2025, 08:30 ET Biomarker-Driven Therapy Launch Strategies for Global Success, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 30, 2025, 08:00 ET Brenig Therapeutics Names Megan McGill as Chief Executive Officer
Therapeutics Founded in 2021 and based in Somerville, MA, Brenig Therapeutics is a biotechnology company committed to pioneering innovative small-molecule therapies for neurodegenerative diseases. Through advanced science and leading AI and
More news about: Brenig Therapeutics Inc
Oct 30, 2025, 07:30 ET Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal
Oct. 30, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates
More news about: Intensity Therapeutics Inc.
Oct 30, 2025, 07:24 ET GITEX Marks Major Expansion with Four New Global Editions Bridging Fast-Rising AI and Tech Ecosystems Worldwide
unicorns in India. Hosted by and organised in partnership with the Government of Karnataka's Department of Electronics, Information Technology and Biotechnology, K-TECH, and Startup Karnataka, the event will serve as a catalyst for global collaboration across AI, semiconductors, advanced manufacturing, quantum
More news about: GITEX
Oct 30, 2025, 07:10 ET GITEX Marks Major Expansion with Four New Global Editions Bridging Fast-Rising AI and Tech Ecosystems Worldwide
unicorns in India. Hosted by and organised in partnership with the Government of Karnataka's Department of Electronics, Information Technology and Biotechnology, K-TECH, and Startup Karnataka, the event will serve as a catalyst for global collaboration across AI, semiconductors, advanced manufacturing, quantum
More news about: GITEX
Oct 30, 2025, 07:05 ET REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program
NAVXpress® suspension-based platform process. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered
More news about: REGENXBIO Inc.
Oct 30, 2025, 07:00 ET NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and neurodegenerative disorders, and Aexon Labs, a biotechnology company advancing next-generation central nervous system ("CNS") therapeutics, today announced the expansion of their DOXA platform with the AEX-6xx
More news about: NLS Pharmaceutics Ltd.
Oct 30, 2025, 07:00 ET Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update
Science's 2025 Top Employers Survey, marking the fifth consecutive year in which Insmed achieved the top ranking. The annual survey polls employees in biotechnology, pharmaceutical, and related industries to determine the 20 best employers, as well as their driving characteristics.
More news about: Insmed Incorporated
Oct 30, 2025, 06:45 ET Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance
Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem (
More news about: Eli Lilly and Company
Oct 30, 2025, 06:30 ET Evommune Announces Commencement of Initial Public Offering
PALO ALTO, Calif., Oct. 30, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that on October 17, 2025, it filed
More news about: Evommune, Inc
Oct 30, 2025, 03:28 ET U.S. FDA grants interchangeability designation to Celltrion's denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)
(aflibercept-boav) as well as the novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information,
More news about: Celltrion
Oct 30, 2025, 02:22 ET Global Times: Benefits of cross-Straits development and reunification: Zhong Taiwen
sides' industrial chains will be deeply integrated, allowing Taiwan's leading industries, such as integrated circuits, precision machinery and biotechnology, to complement the mainland's industrial advantages. Cross-Straits businesses can collaborate to develop and expand globally.
More news about: Global Times
Oct 30, 2025, 01:21 ET Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities
strategic partnership and explore potential collaboration opportunities in ADC development with IntoCell Inc. (KOSDAQ: 287840), a leading Korean biotechnology company specializing in innovative antibody-drug conjugate (ADC) linker and payload platform technologies. Pursuant to this non-exclusive and non-binding
More news about: Piramal Pharma Solutions
Oct 30, 2025, 01:15 ET Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities
strategic partnership and explore potential collaboration opportunities in ADC development with IntoCell Inc. (KOSDAQ: 287840), a leading Korean biotechnology company specializing in innovative antibody-drug conjugate (ADC) linker and payload platform technologies. Pursuant to this non-exclusive and non-binding
More news about: Piramal Pharma Solutions
Oct 29, 2025, 21:00 ET ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection
including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture capital institutions. For more information, please visit:
More news about: Arkbio
Oct 29, 2025, 21:00 ET ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection
including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture capital institutions. For more information, please visit:
More news about: Arkbio
Oct 29, 2025, 20:30 ET Latham & Watkins Names New Partners and Counsel
data-focused transactions and matters in the healthcare and life sciences industry, including emerging and established multinational pharmaceutical, biotechnology, digital health, and medical technology companies and their investors.
More news about: Latham & Watkins LLP
Oct 29, 2025, 20:30 ET Latham & Watkins Names New Partners and Counsel
data-focused transactions and matters in the healthcare and life sciences industry, including emerging and established multinational pharmaceutical, biotechnology, digital health, and medical technology companies and their investors.
More news about: Latham & Watkins LLP
Oct 29, 2025, 20:10 ET Ascletis Selects a Best-in-Class Once-Monthly Subcutaneously Administered Amylin Receptor Agonist, ASC36, for Clinical Development
About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.